Who
Hans Peter Hasler
Director
Company insider
Files Form 4 as: Director, Gain Therapeutics; Director, Minerva Neurosciences; Director, Patheon; Chief Operating Officer, Biogen.
In numbers
- Trades disclosed
- 134
- Buys
- 1
- Sells
- 12
- Bought
- $56K
- Sold
- $17.0M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 6 Feb 2007
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 24 Jun 2025filed 25 Jun 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 5 Dec 2024filed 6 Dec 2024 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 24 Jun 2024filed 26 Jun 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 27 Sep 2023filed 29 Sep 2023 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 23 Jun 2023filed 26 Jun 2023 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 20 Sep 2022filed 22 Sep 2022 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 10 Jun 2022filed 28 Jun 2022 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 11 Jun 2021filed 16 Jun 2021 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Jun 2020filed 12 Jun 2020 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 26 Jun 2019filed 27 Jun 2019 | NERV Minerva NeurosciencesBiotechnology | SEC FORM 4 Bought | $56K10,000 at $5.60 | filing |
| 31 May 2019filed 31 May 2019 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 7 Jun 2018filed 11 Jun 2018 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 10 Dec 2017filed 12 Dec 2017 | NERV Minerva Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 Aug 2017filed 30 Aug 2017 | Patheon | SEC FORM 4 Code U | $590K16,864 at $35.00 | filing |
| 23 Mar 2017filed 27 Mar 2017 | Patheon | SEC FORM 4 Code A | —6,229 at $0.00 | filing |
News
Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026
0 headlines in the last 90 days name Hans Peter Hasler; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.